Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brodalumab: 4-Year US Pharmacovigilance Report.
Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, Jacobson A. Lebwohl M, et al. Among authors: armstrong a. J Drugs Dermatol. 2023 Apr 1;22(4):419-422. doi: 10.36849/JDD.7344. J Drugs Dermatol. 2023. PMID: 37026879
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel.
Zakria D, Brownstone N, Armstrong AW, Boh EE, Koo JYM, Merola JF, Pariser D, Lebwohl M. Zakria D, et al. J Drugs Dermatol. 2023 Jun 1;22(6):588-593. doi: 10.36849/JDD.7432. J Drugs Dermatol. 2023. PMID: 37276166
The panel created 10 consensus statements on how precision medicine can improve patient outcomes, all of which received a unanimous (6/6) vote. CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a …
The panel created 10 consensus statements on how precision medicine can improve patient outcomes, all of which received a unanimous ( …
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis.
Armstrong AW, Reddy R, Khan S, Chovatiya R, Green L, Gold LS, Kwong P, Lebwohl M, Kircik L. Armstrong AW, et al. J Drugs Dermatol. 2023 Aug 1;22(8):736-741. doi: 10.36849/jdd.7453. J Drugs Dermatol. 2023. PMID: 37556522
  For the treatment of psoriasis, the PEG agreed that patients and physicians prefer topical medications that are effective, provide long-lasting results, have a quick onset of action, and "feel good on the skin" with few adverse effects. ...  April W. …
  For the treatment of psoriasis, the PEG agreed that patients and physicians prefer topical medications that are effective, provid …
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, Cirulli J, Goncalves J, Lebwohl M; KOMFORT Trial Investigators. Kim BS, et al. N Engl J Med. 2023 Feb 9;388(6):511-517. doi: 10.1056/NEJMoa2210699. N Engl J Med. 2023. PMID: 36780675 Clinical Trial.
The time to offer treatments for COVID-19.
Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vinjevoll EH, Griffin D, Hung IF. Ngo BT, et al. Among authors: armstrong a. Expert Opin Investig Drugs. 2021 May;30(5):505-518. doi: 10.1080/13543784.2021.1901883. Epub 2021 Apr 23. Expert Opin Investig Drugs. 2021. PMID: 33721548 Free PMC article. Review.
2,165 results